Paclitaxel

Name: Paclitaxel
Brand: Selleck Chemicals
SKU: S1150
Rating: 5 (162 reviews)

For research use only.

Catalog No.S1150 Synonyms: NSC 125973, PTX, Taxol, Onxal

162 publications

CAS No. 33069-62-4

Paclitaxel (NSC 125973, PTX, Taxol, Onxal) is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Selleck's Paclitaxel has been cited by 162 publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Discov, 2019, 9(2):230-247

PubMed: 30373918 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Adv Mater, 2018, 30(43):e1801621

PubMed: 30203567 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(5):650-664

PubMed: 29100014 ( click the link to review the publication )

Clin Cancer Res, 2020, 27 pii: clincanres

PubMed: 32341033 ( click the link to review the publication )

J Cell Biol, 2020, 4;219(5):e201909094

PubMed: 32289147 ( click the link to review the publication )

Theranostics, 2020, 10(6):2727-2743

PubMed: 32194831 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-3466

PubMed: 32054769 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107840

PubMed: 32610141 ( click the link to review the publication )

Oncogene, 2020, 39(2):454-468

PubMed: 31492900 ( click the link to review the publication )

Cancer Lett, 2020, 472:59-69

PubMed: 31866467 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(4) pii: E964

PubMed: 32295077 ( click the link to review the publication )

Cell Death Dis, 2020, 13;11(5):362

PubMed: 32404870 ( click the link to review the publication )

J Cancer, 2020, 26;11(12):3645-3654

PubMed: 32284761 ( click the link to review the publication )

Cell Discov, 2020, 28;6:26

PubMed: 32351706 ( click the link to review the publication )

Front Oncol, 2020, 1.4125

PubMed: 31998647 ( click the link to review the publication )

Int J Mol Sci, 2020, 30;21(3) pii: E903

PubMed: 32019179 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(12):E4452

PubMed: 32585842 ( click the link to review the publication )

Sci Rep, 2020, 15;10(1):337

PubMed: 31941932 ( click the link to review the publication )
Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Pharmacol, 2020, 11:666

PubMed: 32528278 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

Biomed Pharmacother, 2020, 129:110441

PubMed: 32580047 ( click the link to review the publication )

Cancer Manag Res, 2020, 20;12:2641-2651

PubMed: 32368142 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2020, gmaa072

PubMed: 32632453 ( click the link to review the publication )

Cell Biol Int, 2020, 44(2):610-620

PubMed: 31743535 ( click the link to review the publication )

Anticancer Res, 2020, 40(7):3659-3667

PubMed: 32620605 ( click the link to review the publication )

Nat Cancer, 2020, 1(2):235-248

PubMed: 32613204 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1)

PubMed: 32152220 ( click the link to review the publication )

Oncotarget, 2020, 11(30):2873-2888

PubMed: 32774769 ( click the link to review the publication )

Sci Rep, 2020, 10(1):10805

PubMed: 32616817 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 86(2):295-305

PubMed: 32743678 ( click the link to review the publication )

Cancer Biol Ther, 2020, 21(5):452-462

PubMed: 32089062 ( click the link to review the publication )

Life Sci, 2020, 246:117428

PubMed: 32057901 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12308

PubMed: 32704014 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Oncotarget, 2020, 17;11(11):969-981

PubMed: 32215185 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):238-250

PubMed: 30664790 ( click the link to review the publication )

Nat Commun, 2019, 10(1):620

PubMed: 30728358 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5367

PubMed: 31772167 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )
Cell Death Differ, 2019, 10.1038/s41418-019-0441-3

PubMed: 31645676 ( click the link to review the publication )

Cell Death Differ, 2019, 26(11):2300-2313

PubMed: 30778200 ( click the link to review the publication )

J Control Release, 2019, 294:165-175

PubMed: 30557650 ( click the link to review the publication )

Redox Biol, 2019, 22:101131

PubMed: 30735911 ( click the link to review the publication )

Oncogene, 2019, 38(18):3371-3386

PubMed: 30635656 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(12):2079-2094

PubMed: 30825187 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31766723 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):64

PubMed: 31101119 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):660

PubMed: 31506430 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31295851 ( click the link to review the publication )

Cancer Biomark, 2019, 10.3233/CBM-190460

PubMed: 31683459 ( click the link to review the publication )

Cells, 2019, 8(6)

PubMed: 31216647 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-0923

PubMed: 31160383 ( click the link to review the publication )

J Virol, 2019, 93(4)

PubMed: 30487274 ( click the link to review the publication )

Biochem Pharmacol, 2019, 170:113642

PubMed: 31541631 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

J Biol Chem, 2019, 294(46):17471-17486

PubMed: 31594861 ( click the link to review the publication )

J Biol Chem, 2019, 294(20):8161-8170

PubMed: 30940730 ( click the link to review the publication )

J Biol Chem, 2019, 10.1074/jbc.RA119.010732

PubMed: 31628188 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(6):711-719

PubMed: 31585985 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2019, 183:110396

PubMed: 31394424 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

Mol Cell Endocrinol, 2019, 498:110585

PubMed: 31536779 ( click the link to review the publication )

Life Sci, 2019, 224:255-262

PubMed: 30928404 ( click the link to review the publication )
Cell Biosci, 2019, 9:20

PubMed: 30820314 ( click the link to review the publication )

Chem Biol Interact, 2019, 315:108886

PubMed: 31682804 ( click the link to review the publication )

Biomed Rep, 2019, 10(4):218-224

PubMed: 30972217 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:9899-9913

PubMed: 31819487 ( click the link to review the publication )

AAPS PharmSciTech, 2019, 20(5):198

PubMed: 31127389 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1154-1159

PubMed: 31103263 ( click the link to review the publication )

Pathol Res Pract, 2019, 215(10):152606

PubMed: 31500928 ( click the link to review the publication )

Orthop Surg, 2019, 11(1):126-134

PubMed: 30592172 ( click the link to review the publication )

Oncotarget, 2019, 10(49):5011-5019

PubMed: 31489111 ( click the link to review the publication )

World J Clin Oncol, 2019, 10(6):222-233

PubMed: 31367531 ( click the link to review the publication )

Oncotarget, 2019, 10(38):3667-3680

PubMed: 31217901 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4116

PubMed: 30297712 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3197-3203

PubMed: 29559562 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(8):e8238

PubMed: 30104419 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

J Control Release, 2018, 283:223-234

PubMed: 29864473 ( click the link to review the publication )

Cancer Lett, 2018, 420:60-71

PubMed: 29408653 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):743

PubMed: 29970890 ( click the link to review the publication )

J Clin Med, 2018, 7(12)

PubMed: 30477228 ( click the link to review the publication )

Cell Death Dis, 2018, 9(11):1134

PubMed: 30429459 ( click the link to review the publication )
Cell Physiol Biochem, 2018, 47(2):489-504

PubMed: 29794416 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(5):2046-2060

PubMed: 30099455 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

J Cell Sci, 2018, 131(1)

PubMed: 29192060 ( click the link to review the publication )

Biochem Pharmacol, 2018, 155:102-109

PubMed: 29953843 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(10)

PubMed: 30326563 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1116

PubMed: 30319428 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):1225

PubMed: 30526520 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 81(2):255-267

PubMed: 29189915 ( click the link to review the publication )

Fitoterapia, 2018, 125:174-183

PubMed: 29355751 ( click the link to review the publication )

Int J Med Sci, 2018, 15(7):738-747

PubMed: 29910679 ( click the link to review the publication )

DNA Repair (Amst), 2018, 63:1-9

PubMed: 29358095 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Clin Cancer Res., 2017, 23(15):4364-4375

PubMed: 28246274 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(18):E3729-E3738

PubMed: 28416665 ( click the link to review the publication )

Clin Chem, 2017, 63(10):1633-1641

PubMed: 28784692 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

Mol Cancer Ther, 2017, 77(22):6282-6298

PubMed: 28424227 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(7):1377-1388

PubMed: 28416606 ( click the link to review the publication )

J Cancer, 2017, 8(9):1655-1664

PubMed: 28775785 ( click the link to review the publication )
Am J Cancer Res, 2017, 7(4):903-912

PubMed: 28469962 ( click the link to review the publication )

Respir Res, 2017, 18(1):52

PubMed: 28340578 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Int J Oncol, 2017, 51(1):257-268

PubMed: 28534954 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:146

PubMed: 28491824 ( click the link to review the publication )

Biol Reprod, 2017, 97(4):598-611

PubMed: 29025057 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Exp Ther Med, 2017, 14(5):4263-4271

PubMed: 29075340 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51733-51747

PubMed: 28881682 ( click the link to review the publication )

World J Clin Oncol, 2017, 8(1):54-66

PubMed: 28246585 ( click the link to review the publication )

Stem Cell Reports, 2017, 8(6):1617-1629

PubMed: 28552603 ( click the link to review the publication )

Curr Protoc Chem Biol, 2017, 9(2):55-74

PubMed: 28628199 ( click the link to review the publication )

Oncotarget, 2017, 9(1):249-267

PubMed: 29416611 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2082

PubMed: 27182663 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(32):9015-20

PubMed: 27450084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2016, 143:463-471

PubMed: 27037784 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(12):1240-1252

PubMed: 27791595 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

Chin Med J (Engl), 2016, 129(20):2469-2475

PubMed: 27748340 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41811-41824

PubMed: 27248820 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2015, 10.1021/am5090226

PubMed: 25811662 ( click the link to review the publication )

J Control Release, 2015, 220(Pt B):727-37

PubMed: 26390807 ( click the link to review the publication )
Environ Sci Technol, 2015, 49(6):3575-83

PubMed: 25695909 ( click the link to review the publication )

Int J Radiat Oncol, 2015, 91(4):807-16

PubMed: 25752395 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.05.005

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(10):1373-87

PubMed: 26276035 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0134306

PubMed: 26218638 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23358-71

PubMed: 26160840 ( click the link to review the publication )

Biomacromolecules, 2014, 15(11):4187-94

PubMed: 25251833 ( click the link to review the publication )

Mol Pharmacol, 2014, 85(3):408-19

PubMed: 24353313 ( click the link to review the publication )

Surgery, 2014, 10.1016/j.surg.2014.10.007

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):392-7

PubMed: 25268318 ( click the link to review the publication )

J Nanopart Res, 2014, 16:2340

PubMed: ( click the link to review the publication )

J Gen Virol, 2013, 94(Pt 12):2750-8

PubMed: 24062531 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2012, 71(13):4707-19

PubMed: 21555371 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Bioorg Med Chem, 2012, 21(4):922-31

PubMed: 23306053 ( click the link to review the publication )

RSC Adv, 2011, 1:884-892

PubMed: ( click the link to review the publication )

Gynecol Oncol, 2003, 90(3 Pt 2):S16-21

PubMed: 13129491 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description

Paclitaxel (NSC 125973, PTX, Taxol, Onxal) is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Targets

Microtubule (human endothelial cells) ^[1]

0.1 pM

In vitro

Paclitaxel inhibits non-endothelial type human cells at 10⁴ - to 10⁵ -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. ^[1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. ^[2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
TE-15	NV3FSmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3HdFBKSzVyPUCuNFAxOjh5IN88US=>	NUjid2Z6W0GQR1XS
LC-2-ad	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\jToZKSzVyPUCuNFAxOzF5IN88US=>	MmDnV2FPT0WU
RL95-2	NXfoV4FxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1P4cWlEPTB;MD6wNFA3PjhizszN	MWDTRW5ITVJ?
MZ1-PC	NIHxXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLr[2FYUUN3ME2wMlAxODd{OTFOwG0>	M{LlS3NCVkeHUh?=
TE-8	MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnL6TWM2OD1yLkCwNVE4KM7:TR?=	MVnTRW5ITVJ?
SW954	NXqx[3B[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmm5TWM2OD1yLkCwNVE6KM7:TR?=	NY\uN5B1W0GQR1XS
TE-11	NHTRc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:yNmNCUUN3ME2wMlAxOTJ\|IN88US=>	M{Pl[3NCVkeHUh?=
PSN1	M2rOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\QSog4UUN3ME2wMlAxOTNizszN	M{TpXnNCVkeHUh?=
MOLT-4	Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwMECxOFkh\|ryP	MUPTRW5ITVJ?
697	NGexOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXSOIxKSzVyPUCuNFAyPSEQvF2=	MV3TRW5ITVJ?
ETK-1	M{S0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXCTWM2OD1yLkCwNVUzKM7:TR?=	NHzITW1USU6JRWK=
TE-10	MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMECxOVQh\|ryP	M33iSHNCVkeHUh?=
HUTU-80	NYLlOHZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMECxOlgh\|ryP	M37a[3NCVkeHUh?=
NTERA-S-cl-D1	NFu4[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMECyNFkh\|ryP	NEjpeGxUSU6JRWK=
MFH-ino	NUXLXoM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml33TWM2OD1yLkCwNlY5KM7:TR?=	MlTYV2FPT0WU
IA-LM	NGGwTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M164emlEPTB;MD6wNFI5KM7:TR?=	MkTyV2FPT0WU
MC116	NFiw[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHe4blVKSzVyPUCuNFAzQDlizszN	NHPQOGNUSU6JRWK=
RKO	M3\VW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMECyPVgh\|ryP	Mn3tV2FPT0WU
MRK-nu-1	M3vROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTvTWM2OD1yLkCwNlk6KM7:TR?=	MlL2V2FPT0WU
VA-ES-BJ	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwMECzJO69VQ>?	MYDTRW5ITVJ?
KALS-1	NXuw[4VMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfrfJpKSzVyPUCuNFA{ODhizszN	NEToUpZUSU6JRWK=
BB30-HNC	M1H6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrLR2dKUUN3ME2wMlAxOzF2IN88US=>	NXS5SYRVW0GQR1XS
ACN	MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPjS2NKSzVyPUCuNFA{OTZizszN	M4PzeHNCVkeHUh?=
TE-9	NVHCWJFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjXTWM2OD1yLkCwN\|I3KM7:TR?=	M4LCcnNCVkeHUh?=
SIG-M5	NYjYR2c{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXnT4RKSzVyPUCuNFA{OjdizszN	MYnTRW5ITVJ?
no-10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXOeXdKSzVyPUCuNFA{PjJizszN	M2XrR3NCVkeHUh?=
EW-1	MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwMECzO\|Eh\|ryP	Mm\rV2FPT0WU
SK-LMS-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULhbmVwUUN3ME2wMlAxPDBzIN88US=>	M{LNRnNCVkeHUh?=
GT3TKB	MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknwTWM2OD1yLkCwOFM1KM7:TR?=	NXjieoRzW0GQR1XS
ES4	NVjVPYpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofuTWM2OD1yLkCwOFQ6KM7:TR?=	M2TXfHNCVkeHUh?=
IMR-5	NXPHSYR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jvUGlEPTB;MD6wNFQ2KM7:TR?=	NGj5SI9USU6JRWK=
NCI-H1648	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjxR3QxUUN3ME2wMlAxPDZ7IN88US=>	M2fxdnNCVkeHUh?=
MV-4-11	NXX3UXJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMEC0O\|Uh\|ryP	MknoV2FPT0WU
SK-UT-1	M3XhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{K2VmlEPTB;MD6wNFQ5KM7:TR?=	NWHaV5NUW0GQR1XS
NB13	NYjodIUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfLT2FlUUN3ME2wMlAxPDlzIN88US=>	MWjTRW5ITVJ?
DJM-1	MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHibYpKSzVyPUCuNFA2OyEQvF2=	NF61c5VUSU6JRWK=
ES8	NYPWPIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzpd3BSUUN3ME2wMlAxPTN6IN88US=>	NWXLemhzW0GQR1XS
TE-6	MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMEC1O{DPxE1?	MVjTRW5ITVJ?
KS-1	MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3j6eGlEPTB;MD6wNFU5OiEQvF2=	MWrTRW5ITVJ?
TE-1	NHjpbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4KwdWlEPTB;MD6wNFYxPiEQvF2=	M3u2bnNCVkeHUh?=
ATN-1	M4P5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1ezUWlEPTB;MD6wNFYxQSEQvF2=	NF7SfIVUSU6JRWK=
A4-Fuk	M{TlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXBTWM2OD1yLkCwOlEyKM7:TR?=	NYLPTGRtW0GQR1XS
ALL-PO	MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC1NZYxUUN3ME2wMlAxPjNizszN	M1XZVXNCVkeHUh?=
BE-13	NInETY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3S5XWlEPTB;MD6wNFY{PiEQvF2=	MU\TRW5ITVJ?
KM12	MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHteXRKSzVyPUCuNFA3OzdizszN	MVLTRW5ITVJ?
NOS-1	NX6yRVVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwMEC2OUDPxE1?	NYnaNpRpW0GQR1XS
SW962	Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLlNY5KSzVyPUCuNFA3PjJizszN	MnXHV2FPT0WU
OCUB-M	M33rRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{K2UWlEPTB;MD6wNFY3OiEQvF2=	M1zFfnNCVkeHUh?=
NCI-H510A	NWSxU45QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XZTmlEPTB;MD6wNFY3PSEQvF2=	NE[4SpFUSU6JRWK=
EW-16	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLJTWM2OD1yLkCwOlk1KM7:TR?=	NFfQW2dUSU6JRWK=
KGN	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTkPYFKSzVyPUCuNFA4OTJizszN	M1f4RnNCVkeHUh?=
LS-411N	M1OwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnX6TWM2OD1yLkCwO\|E4KM7:TR?=	NGLZZ5NUSU6JRWK=
Becker	M135SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYX3flhQUUN3ME2wMlAxPzJizszN	NITYZ2hUSU6JRWK=
HC-1	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVi2epp7UUN3ME2wMlAxPzJzIN88US=>	M1f6eHNCVkeHUh?=
CESS	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMEC3N\|ch\|ryP	NWD2VYVxW0GQR1XS
KURAMOCHI	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHsU5hJUUN3ME2wMlAxPzR6IN88US=>	MknuV2FPT0WU
TGBC24TKB	Mn3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDsNZhWUUN3ME2wMlAxPzV{IN88US=>	Mmn3V2FPT0WU
SW982	M3:0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwMEC3OlYh\|ryP	MVfTRW5ITVJ?
HCE-4	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITxUZVKSzVyPUCuNFA4PjdizszN	NYDET2hGW0GQR1XS
LOUCY	M1r4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13mOmlEPTB;MD6wNFc4PSEQvF2=	MX\TRW5ITVJ?
8-MG-BA	NV36TYNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTBwMEC3PVYh\|ryP	NWTvPHBzW0GQR1XS
HT-144	NX\vSGlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHpT41lUUN3ME2wMlAxQCEQvF2=	NX\tNmdbW0GQR1XS
LXF-289	MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMEC4NVgh\|ryP	MYXTRW5ITVJ?
RS4-11	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX4bIFKSzVyPUCuNFA5OzZizszN	M3;iTnNCVkeHUh?=
DEL	NXrxfXN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{D3RWlEPTB;MD6wNFg1PSEQvF2=	MX3TRW5ITVJ?
OCI-AML2	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwMEC4OVIh\|ryP	Mm\zV2FPT0WU
CCRF-CEM	M4XZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInIeWZKSzVyPUCuNFA5PzFizszN	MWrTRW5ITVJ?
A388	M1;adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwMEC4O\|Qh\|ryP	NFX4UmtUSU6JRWK=
KNS-42	MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLzV2pKSzVyPUCuNFA5QTFizszN	NVXZRollW0GQR1XS
OVCAR-4	M171Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3STWM2OD1yLkCwPVA1KM7:TR?=	MVLTRW5ITVJ?
NCI-H1355	NHP4OmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknKTWM2OD1yLkCwPVE1KM7:TR?=	M{foPXNCVkeHUh?=
BL-70	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zZPWlEPTB;MD6wNFk{KM7:TR?=	MkLvV2FPT0WU
BL-41	M{\wdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLRTWM2OD1yLkCwPVM1KM7:TR?=	MojvV2FPT0WU
A101D	NV7BNFdoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwMEC5OkDPxE1?	NYTFUlhSW0GQR1XS
HL-60	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\5RnJKSzVyPUCuNFA6PjZizszN	NGCwcm1USU6JRWK=
COR-L279	M3LFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnFfYM2UUN3ME2wMlAxQTl7IN88US=>	NUn6RnJ[W0GQR1XS
NCI-SNU-16	NGXvUXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMEGwNFgh\|ryP	NUPCWG9HW0GQR1XS
Calu-6	NHHMSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMEGwNVIh\|ryP	MorCV2FPT0WU
SR	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHQR2RnUUN3ME2wMlAyODJ4IN88US=>	MXHTRW5ITVJ?
QIMR-WIL	NYW4bnJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwMEGwN\|Mh\|ryP	MnG4V2FPT0WU
LB647-SCLC	M1f1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jNWmlEPTB;MD6wNVA2OSEQvF2=	MkXUV2FPT0WU
RPMI-8226	NFHWbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTBwMEGxNFIh\|ryP	NWHnbWc1W0GQR1XS
SK-PN-DW	M4HGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwMEGxNVIh\|ryP	NX;tUJQxW0GQR1XS
SF268	NHHldXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTqTWM2OD1yLkCxNVUyKM7:TR?=	M2fleXNCVkeHUh?=
HD-MY-Z	MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;VTWlEPTB;MD6wNVE3OyEQvF2=	MlTaV2FPT0WU
DOHH-2	Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PTfWlEPTB;MD6wNVIxOyEQvF2=	M2nxXXNCVkeHUh?=
SCC-3	M{LTemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPuclREUUN3ME2wMlAyOjB2IN88US=>	NXPmfVVMW0GQR1XS
ST486	M{XDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[0TWM2OD1yLkCxNlA1KM7:TR?=	NYrOcYVLW0GQR1XS
NALM-6	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGm1WVFKSzVyPUCuNFEzOTRizszN	NW[4ZVlJW0GQR1XS
NCI-H1436	MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYT1VGptUUN3ME2wMlAyOjNzIN88US=>	M4rHenNCVkeHUh?=
KE-37	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMEGyN\|Qh\|ryP	NULlUJRtW0GQR1XS
RPMI-8402	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLtd4JJUUN3ME2wMlAyOjV4IN88US=>	NIr0RVdUSU6JRWK=
RXF393	NEXvdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHLTWM2OD1yLkCxNlU4KM7:TR?=	MUHTRW5ITVJ?
KARPAS-45	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonHTWM2OD1yLkCxNlch\|ryP	MmrBV2FPT0WU
HOP-62	M1X5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMEGyO\|Yh\|ryP	M{TUNHNCVkeHUh?=
ES1	Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fPWmlEPTB;MD6wNVI5QCEQvF2=	MYrTRW5ITVJ?
L-363	NXLMWnZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHGUZgxUUN3ME2wMlAyOzVzIN88US=>	M3zjVXNCVkeHUh?=
GI-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTxem5QUUN3ME2wMlAyOzd\|IN88US=>	MYLTRW5ITVJ?
CTV-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETIWVlKSzVyPUCuNFE1PzhizszN	NX;WbZU3W0GQR1XS
TE-5	MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXntUnpVUUN3ME2wMlAyPDl4IN88US=>	NEG1UW1USU6JRWK=
SNU-C2B	NFf4RZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkT2TWM2OD1yLkCxOFk3KM7:TR?=	MlnzV2FPT0WU
K-562	NELrS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DvR2lEPTB;MD6wNVUyPiEQvF2=	MnrMV2FPT0WU
SNB75	NEnrfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3seIhKSzVyPUCuNFE2PCEQvF2=	NVrxUHlKW0GQR1XS
MOLT-13	NGrKcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMEG2N\|ch\|ryP	NVy5XXZKW0GQR1XS
LS-123	NV3IPW1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NImy[JVKSzVyPUCuNFE3PjRizszN	MmTqV2FPT0WU
NCI-SNU-5	NYDmb3NZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4C1S2lEPTB;MD6wNVcxOSEQvF2=	MmHtV2FPT0WU
Daudi	MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nn[mlEPTB;MD6wNVcxQCEQvF2=	NH;nZ3JUSU6JRWK=
A253	MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jKOGlEPTB;MD6wNVc{QCEQvF2=	NYrGcXVIW0GQR1XS
TGBC1TKB	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGX5XZNKSzVyPUCuNFE4PTJizszN	Mmj3V2FPT0WU
SJSA-1	NWXN[nBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYX0d2t1UUN3ME2wMlAyPzZ5IN88US=>	MUjTRW5ITVJ?
NCCIT	MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\wN2lEPTB;MD6wNVc3QSEQvF2=	MlryV2FPT0WU
NCI-H69	M2XOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnreGZOUUN3ME2wMlAyPzd6IN88US=>	MVLTRW5ITVJ?
SH-4	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmW5TWM2OD1yLkCxPFk2KM7:TR?=	MUjTRW5ITVJ?
HCC1187	MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjkUlh2UUN3ME2wMlAyQTJ2IN88US=>	NGK2OY9USU6JRWK=
HCC1599	NY\IcJJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrzTWM2OD1yLkCyNFIh\|ryP	NVr2T4doW0GQR1XS
ONS-76	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMEKwN\|Yh\|ryP	M{X2UXNCVkeHUh?=
KU812	M13YTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zmbGlEPTB;MD6wNlA{QSEQvF2=	MXvTRW5ITVJ?
ML-2	MlzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMEKwOFch\|ryP	NWnwWVI2W0GQR1XS
HCE-T	NGm5Z3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;uTZBKUUN3ME2wMlAzODl{IN88US=>	NWLQNnNGW0GQR1XS
NCI-H446	M1u5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\pSFZKSzVyPUCuNFIyOTJizszN	NEDHcpFUSU6JRWK=
RPMI-6666	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLPTWM2OD1yLkCyNVQ6KM7:TR?=	NHPTNpJUSU6JRWK=
MOLT-16	NFS4WYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;DOZRLUUN3ME2wMlAzOTV\|IN88US=>	MUPTRW5ITVJ?
JiyoyeP-2003	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTzTWM2OD1yLkCyNVc3KM7:TR?=	NGnRPWlUSU6JRWK=
MHH-PREB-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIW4ZYNKSzVyPUCuNFIyQTFizszN	M1P0SHNCVkeHUh?=
MC-CAR	NX[zUpRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrjbGI{UUN3ME2wMlAzOzJ4IN88US=>	MWjTRW5ITVJ?
BC-3	M3zibGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrDVFdOUUN3ME2wMlAzOzR2IN88US=>	M{nReXNCVkeHUh?=
KINGS-1	Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIS5N21KSzVyPUCuNFI{PTVizszN	NHjCZ4VUSU6JRWK=
PF-382	MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPLTWM2OD1yLkCyN\|c5KM7:TR?=	Mln0V2FPT0WU
J-RT3-T3-5	M2TKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfETWM2OD1yLkCyN\|g{KM7:TR?=	MmX3V2FPT0WU
SF539	NY\BUWlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TkcmlEPTB;MD6wNlQxOSEQvF2=	MWPTRW5ITVJ?
LB831-BLC	M{PM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjaVlNNUUN3ME2wMlAzPDh3IN88US=>	MXzTRW5ITVJ?
DMS-114	M{fuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILtd4pKSzVyPUCuNFI2ODJizszN	MV;TRW5ITVJ?
LB1047-RCC	NHXzfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHQV5VEUUN3ME2wMlAzPTFizszN	NVvNR3NZW0GQR1XS
LB771-HNC	NX\lWGlkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMEK1N\|Qh\|ryP	NVXmXJZTW0GQR1XS
BB65-RCC	NEnyeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwMEK1N\|Qh\|ryP	M3PPXXNCVkeHUh?=
BV-173	NH3XPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvHTWM2OD1yLkCyOVU1KM7:TR?=	M3TXVXNCVkeHUh?=
ARH-77	M1K0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn21TWM2OD1yLkCyOlAyKM7:TR?=	NHvMUm5USU6JRWK=
IST-MEL1	NVfsd\|hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;2V\|dzUUN3ME2wMlAzPjJ\|IN88US=>	NX\1O5pFW0GQR1XS
NB1	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfMW4hUUUN3ME2wMlAzPjh5IN88US=>	NXjC[W5GW0GQR1XS
EoL-1-cell	M{HOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PRVmlEPTB;MD6wNlY5QCEQvF2=	NF76d5pUSU6JRWK=
KY821	M{T6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:wVJdKSzVyPUCuNFI3QTdizszN	NWG5XGtMW0GQR1XS
CMK	NUj1NHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzpfpdKSzVyPUCuNFI4OzRizszN	NHvZUpJUSU6JRWK=
NCI-H2126	NE\3SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwMEK3Olgh\|ryP	MmrDV2FPT0WU
NCI-H526	MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDiUINKSzVyPUCuNFI5QTFizszN	M1T5THNCVkeHUh?=
COLO-684	M2C4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMEK5NFgh\|ryP	NF7UTm1USU6JRWK=
NCI-H747	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{P5emlEPTB;MD6wNlk{OyEQvF2=	NEDEbFBUSU6JRWK=
JAR	NGrrSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7xNmV{UUN3ME2wMlAzQTR4IN88US=>	NEHxOWhUSU6JRWK=
MEG-01	Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXux[JVPUUN3ME2wMlAzQTd6IN88US=>	M{TIbnNCVkeHUh?=
MONO-MAC-6	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7wc5pyUUN3ME2wMlA{ODJ\|IN88US=>	MVTTRW5ITVJ?
IST-SL1	M2jmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMEOwOFIh\|ryP	M1jSSnNCVkeHUh?=
CPC-N	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmC2TWM2OD1yLkCzNFc6KM7:TR?=	NEXvSnJUSU6JRWK=
NCI-H1963	MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMEOxN\|Eh\|ryP	MYrTRW5ITVJ?
K052	NVTaUIJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMEOyOFch\|ryP	MVzTRW5ITVJ?
KM-H2	NIrNNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFf4fYhKSzVyPUCuNFM{ODdizszN	M4jGU3NCVkeHUh?=
TE-12	NYHjOoo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPLTWM2OD1yLkCzN\|A6KM7:TR?=	MljoV2FPT0WU
TK10	M{TRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfrTWM2OD1yLkCzN\|U3KM7:TR?=	NWfvbFNoW0GQR1XS
NMC-G1	NU\4O3NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLxTIRzUUN3ME2wMlA{PDV{IN88US=>	NHv2bG1USU6JRWK=
no-11	M4nKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWX5dZhrUUN3ME2wMlA{PDd6IN88US=>	MWTTRW5ITVJ?
NCI-H524	MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHWdphKSzVyPUCuNFM2OjlizszN	M1\FUHNCVkeHUh?=
MHH-CALL-2	NX7ib2ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMEO1OlIh\|ryP	NIXvR5ZUSU6JRWK=
GB-1	M2DLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPhZmdKSzVyPUCuNFM3KM7:TR?=	NFe3T25USU6JRWK=
OPM-2	NUPwTHBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2[zXWlEPTB;MD6wN\|Y4OyEQvF2=	MmnPV2FPT0WU
RH-1	M4G3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jTOGlEPTB;MD6wN\|gyQSEQvF2=	MkjUV2FPT0WU
NCI-H64	NX;NbVZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfZTFBKSzVyPUCuNFM5PTdizszN	MVnTRW5ITVJ?
EVSA-T	NYGxRoV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwMEO5NlMh\|ryP	MWTTRW5ITVJ?
KARPAS-299	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfNUZNGUUN3ME2wMlA{QThizszN	M37ae3NCVkeHUh?=
MZ7-mel	NInLV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTyTWM2OD1yLkC0NFQh\|ryP	Mn30V2FPT0WU
LB373-MEL-D	Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFi2dmlKSzVyPUCuNFQyODVizszN	MX;TRW5ITVJ?
HEL	NIDwPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjtTZVKSzVyPUCuNFQyPCEQvF2=	M2X1b3NCVkeHUh?=
SW872	NFjGUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nVRWlEPTB;MD6wOFIyKM7:TR?=	Ml\XV2FPT0WU
DU-4475	NGDZT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;PTWM2OD1yLkC0NlQ1KM7:TR?=	NFnUUnRUSU6JRWK=
IST-SL2	NGLaVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTwS5gzUUN3ME2wMlA1Ojd3IN88US=>	NGLFPVRUSU6JRWK=
NCI-H82	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwMESzNFch\|ryP	MWrTRW5ITVJ?
LC4-1	M3;yZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfXTlZKSzVyPUCuNFQ{PTFizszN	M3\adXNCVkeHUh?=
HDLM-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\FflRKSzVyPUCuNFQ{QTJizszN	M{C2Z3NCVkeHUh?=
MMAC-SF	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;FeWlEPTB;MD6wOFU{PCEQvF2=	M1:2bHNCVkeHUh?=
L-540	NUnrO3h7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX72e\|BtUUN3ME2wMlA1PjN7IN88US=>	MoTEV2FPT0WU
MZ2-MEL	NWr2UGEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3se4lxUUN3ME2wMlA1PzR{IN88US=>	MUfTRW5ITVJ?
LU-134-A	MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMES3O\|Mh\|ryP	MlX5V2FPT0WU
UACC-257	NYLCUohmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnv2TWM2OD1yLkC0PFQ6KM7:TR?=	MoLTV2FPT0WU
NCI-H1581	NF\lSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HlTGlEPTB;MD6wOFk2OyEQvF2=	NW\idZMzW0GQR1XS
NB17	Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnz4TWM2OD1yLkC0PVc6KM7:TR?=	M2LEVXNCVkeHUh?=
SBC-1	NIXIbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDNTWM2OD1yLkC1NFQzKM7:TR?=	NUjSd4tbW0GQR1XS
TALL-1	NGHaXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Moj3TWM2OD1yLkC1NFQ2KM7:TR?=	Mme4V2FPT0WU
NCI-H1304	NF:4T5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMEWyNFgh\|ryP	NWLKbm5QW0GQR1XS
NEC8	NG[xXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4ra[2lEPTB;MD6wOVI5PiEQvF2=	Ml32V2FPT0WU
CAL-148	MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMEW0N\|kh\|ryP	MWLTRW5ITVJ?
CGTH-W-1	MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vySmlEPTB;MD6wOVQ1QSEQvF2=	M1TZS3NCVkeHUh?=
NCI-H889	M3THUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TZb2lEPTB;MD6wOVU6OiEQvF2=	M3HCVXNCVkeHUh?=
GR-ST	Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMEW2NlEh\|ryP	MVLTRW5ITVJ?
KARPAS-422	M{PjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PTUWlEPTB;MD6wOVY2KM7:TR?=	NWTDTldHW0GQR1XS
RPMI-8866	Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwMEW3NVIh\|ryP	NF2wWJJUSU6JRWK=
SCLC-21H	NID1ZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzQXZdKSzVyPUCuNFU5QDRizszN	M4nWbnNCVkeHUh?=
COR-L88	NX:0UnM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMEW5Nlch\|ryP	NUP0do1SW0GQR1XS
LU-139	NYqwVXB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDPTWM2OD1yLkC1PVg3KM7:TR?=	MkX3V2FPT0WU
SF126	NEPoXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LtT2lEPTB;MD6wOlE{OyEQvF2=	NWm3emFTW0GQR1XS
NCI-H1882	NIT1UGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XrUmlEPTB;MD6wOlQzPCEQvF2=	MkjSV2FPT0WU
EW-24	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwME[0PFMh\|ryP	NI[wZ2hUSU6JRWK=
CP67-MEL	NEThN\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33lZWlEPTB;MD6wOlgyKM7:TR?=	MnG4V2FPT0WU
DG-75	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwME[4PVkh\|ryP	M3PpdXNCVkeHUh?=
LOXIMVI	NV:3SGRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzrTWM2OD1yLkC3NFI5KM7:TR?=	M4PiRnNCVkeHUh?=
HH	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnaSY1CUUN3ME2wMlA4OTV5IN88US=>	MXHTRW5ITVJ?
K5	M3XBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TRNGlEPTB;MD6wO\|IzPiEQvF2=	M3KzcXNCVkeHUh?=
EC-GI-10	MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2Xqe2lEPTB;MD6wO\|I2PyEQvF2=	Mk\sV2FPT0WU
SK-N-DZ	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTBwMEezNFch\|ryP	M{fH[HNCVkeHUh?=
A3-KAW	NXLJVJJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwMEezOVEh\|ryP	NUHpTlN7W0GQR1XS
MLMA	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TORWlEPTB;MD6wO\|Q3PSEQvF2=	MmrOV2FPT0WU
LB996-RCC	M4XtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfaTWM2OD1yLkC3O\|A4KM7:TR?=	MlzTV2FPT0WU
OS-RC-2	NXGye49lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;lbGxKSzVyPUCuNFc4PDhizszN	NGq1N\|FUSU6JRWK=
CTB-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMEe4NUDPxE1?	NHrYWFFUSU6JRWK=
IST-MES1	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mln0TWM2OD1yLkC3PVEzKM7:TR?=	NWT1eWsyW0GQR1XS
LS-1034	NELHXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEiwN\|Uh\|ryP	MYXTRW5ITVJ?
HT	NGfPW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfwZ2RZUUN3ME2wMlA5ODh4IN88US=>	NXrL[mtlW0GQR1XS
NCI-H2141	NIXhcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWW2bpVYUUN3ME2wMlA5OSEQvF2=	MXLTRW5ITVJ?
LB2518-MEL	M3WzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvXR49qUUN3ME2wMlA5OTRzIN88US=>	M3K0bHNCVkeHUh?=
GI-ME-N	NVXPc4VGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\QWHZCUUN3ME2wMlA5PDV{IN88US=>	M2\FTXNCVkeHUh?=
TGW	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMEi2NFch\|ryP	MnzSV2FPT0WU
SK-NEP-1	MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrHeZhKSzVyPUCuNFg3PDFizszN	NYDtNJpKW0GQR1XS
NOMO-1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEmyO\|Uh\|ryP	NYDlVlFUW0GQR1XS
ES6	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPHdZVKSzVyPUCuNFk2QDlizszN	MmLDV2FPT0WU
NCI-H209	NUfUTGp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33VWmlEPTB;MD6wPVc5PiEQvF2=	MWjTRW5ITVJ?
GAK	NXrTcXdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTSOlJIUUN3ME2wMlExOTZizszN	MUXTRW5ITVJ?
BC-1	M{XOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvvepJRUUN3ME2wMlExOzZzIN88US=>	M1PoUHNCVkeHUh?=
KLE	M4j5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHFWHBLUUN3ME2wMlExPDR\|IN88US=>	NUXLRYptW0GQR1XS
EW-3	NUXyNIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\KOGlEPTB;MD6xNFk5KM7:TR?=	MlfsV2FPT0WU
NKM-1	NVnqcJN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzsR5hjUUN3ME2wMlEyOSEQvF2=	M{Tqc3NCVkeHUh?=
D-336MG	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjNRVNKSzVyPUCuNVEzPDRizszN	NIXxTVZUSU6JRWK=
NB69	NH\l[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMUGzNFEh\|ryP	MXPTRW5ITVJ?
D-263MG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnwTWM2OD1yLkGxO\|EzKM7:TR?=	NF70W3hUSU6JRWK=
KP-N-YS	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInnRoFKSzVyPUCuNVIzQTFizszN	MkLiV2FPT0WU
NCI-H1155	NIDiPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3Kd5dwUUN3ME2wMlEzPTV6IN88US=>	NVP2fZN2W0GQR1XS
BOKU	NHniRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPVNVVKSzVyPUCuNVI2PzlizszN	MlHmV2FPT0WU
LAMA-84	M{DRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\LTWM2OD1yLkGyPVkh\|ryP	M1ezNnNCVkeHUh?=
Raji	MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTEO3RKSzVyPUCuNVMyOTdizszN	MUjTRW5ITVJ?
LU-65	M4i4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T6XGlEPTB;MD6xN\|MxPyEQvF2=	MXfTRW5ITVJ?
NCI-H187	MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nZfmlEPTB;MD6xN\|kzPCEQvF2=	M33ue3NCVkeHUh?=
GCIY	NEPOWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonnTWM2OD1yLkG0PVAyKM7:TR?=	MVHTRW5ITVJ?
NCI-H2107	M4HoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwMUWwPEDPxE1?	MYrTRW5ITVJ?
NCI-H1522	MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwMUWyOlYh\|ryP	NXraNo1ZW0GQR1XS
NB6	M1ThZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1viSWlEPTB;MD6xOVYzOyEQvF2=	NGjoO\|lUSU6JRWK=
EM-2	M2X4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzIV\|BoUUN3ME2wMlE2PzB4IN88US=>	M3\LdHNCVkeHUh?=
HCC2218	NVK2S2hST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY[2SY0{UUN3ME2wMlE2QThizszN	MWfTRW5ITVJ?
NCI-H748	MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3L5SmlEPTB;MD6xOlM4PiEQvF2=	MX3TRW5ITVJ?
MS-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{K0R2lEPTB;MD6xOlU{PyEQvF2=	NYfXZ4dGW0GQR1XS
NB5	NIX3dpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTwTWM2OD1yLkG2OVk4KM7:TR?=	MUjTRW5ITVJ?
OMC-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fGW2lEPTB;MD6xOlY5QCEQvF2=	M3e0ZnNCVkeHUh?=
NCI-H345	M13RSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmr5TWM2OD1yLkG2PVI5KM7:TR?=	MYDTRW5ITVJ?
L-428	NVnDcWhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHm5bHRKSzVyPUCuNVY6PDVizszN	NHK4U\|lUSU6JRWK=
SCH	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnkW\|RKSzVyPUCuNVg3QDVizszN	NVLYc5ExW0GQR1XS
NCI-H1417	NInqdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjCUFJkUUN3ME2wMlE6OjJ5IN88US=>	NGW4b49USU6JRWK=
COLO-320-HSR	NW\McFEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGG4O2tKSzVyPUCuNVk2OzJizszN	NYjDPXp6W0GQR1XS
BT-474	NFPwPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLqbVBKSzVyPUCuNlA5QTJizszN	MVrTRW5ITVJ?
GDM-1	NUG4NJJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;aTWM2OD1yLkKxPVcyKM7:TR?=	MVvTRW5ITVJ?
NCI-H2196	NWDUZW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwMkKyN\|Uh\|ryP	NVHuOW1YW0GQR1XS
KP-N-RT-BM-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwMkKzOFkh\|ryP	MYjTRW5ITVJ?
KNS-81-FD	NEH1XmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3uyN2lEPTB;MD6yNlk2QCEQvF2=	MUHTRW5ITVJ?
COLO-668	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF34e4lKSzVyPUCuNlM3PzVizszN	M2WxXnNCVkeHUh?=
C2BBe1	M1:xPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LRe2lEPTB;MD6yOlc1PyEQvF2=	NWTEOFZ{W0GQR1XS
Ramos-2G6-4C10	M1rNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;ifHVKSzVyPUCuNlY6PTRizszN	MYrTRW5ITVJ?
CAS-1	NIC0Zm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmT2TWM2OD1yLkK3NFk3KM7:TR?=	MlzvV2FPT0WU
GOTO	NXzTSpZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3LTWM2OD1yLkK3PFk1KM7:TR?=	NH;kZ2JUSU6JRWK=
LP-1	M4raeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzJRYlwUUN3ME2wMlI5ODV5IN88US=>	M4\FT3NCVkeHUh?=
NCI-SNU-1	M13wS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMkm0NlIh\|ryP	M1nK[nNCVkeHUh?=
EB-3	NITWVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPMTWM2OD1yLkK5PVc6KM7:TR?=	M4DNenNCVkeHUh?=
MHH-NB-11	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXe1Z4RSUUN3ME2wMlMxPDB{IN88US=>	MX3TRW5ITVJ?
SK-N-FI	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwM{G2PVIh\|ryP	NH7Pd3VUSU6JRWK=
HCC2157	NXHCb3dXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVW0VWR5UUN3ME2wMlM{QTF\|IN88US=>	NE\3R4RUSU6JRWK=
SIMA	NX7VZ\|lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3z3N2lEPTB;MD6zOFU5OSEQvF2=	NE\hN2FUSU6JRWK=
MDA-MB-134-VI	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFz3PJVKSzVyPUCuN\|Y6OjhizszN	NUSyW2l{W0GQR1XS
NCI-H1694	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3TcY9KSzVyPUCuN\|ch\|ryP	NEjjXVhUSU6JRWK=
EHEB	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwM{mwPFUh\|ryP	NYHUbpltW0GQR1XS
U-266	NHnXOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXv2dJRjUUN3ME2wMlM6QDR4IN88US=>	NYLYPZpTW0GQR1XS
LC-1F	M{LEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnX5TWM2OD1yLkSzO\|Y2KM7:TR?=	Mn7EV2FPT0WU
SHP-77	NH3WR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3wU5dUUUN3ME2wMlQ4QDV3IN88US=>	NGrNNHBUSU6JRWK=
LS-513	NHTCe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7ETWM2OD1yLkS5N\|A4KM7:TR?=	MkHvV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK / ERK; PubMed: 20068074 Clin Cancer Res Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells. MARCKS (pSer159/163); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. Src (pTyr416); PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis. p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; PubMed: 29849942 Oncotarget OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot. Id1; PubMed: 25344919 Oncotarget (A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner. MARCKS; PubMed: 26015406 Oncotarget Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.	20068074 26015406 29849942 25344919
Growth inhibition assay	Cell viability; PubMed: 28823711 Biol Psychiatry Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.	28823711
Immunofluorescence	α-tubulin; PubMed: 22904633 Int J Nanomedicine Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel. Rab11a/BV9; PubMed: 29290815 Theranostics Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).	22904633 29290815

In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. ^[4]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
Concentrations: 0.1-100 pM
Incubation Time: 72 hours
Method:
Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.

(Only for Reference)

Animal Research:

^[4]

- Collapse

Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
Dosages: 20 mg/kg
Administration: Administered via i.v.
(Only for Reference)

References

[4] Chang J, et al. Breast Cancer Res Treat. 2012.

- Collapse

Solubility (25°C)

In vitro	DMSO	171 mg/mL (200.25 mM)
	Water	Insoluble
	Ethanol	''18 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Paclitaxel SDF

Molecular Weight	853.91
Formula	C₄₇H₅₁NO₁₄
CAS No.	33069-62-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NSC 125973, PTX, Taxol, Onxal
Smiles	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04252768	Not yet recruiting	Drug: Eftilagimod Alpha\|Drug: Paclitaxel	Metastatic Breast Cancer	Immutep S.A.	June 2021	Phase 1
NCT04526470	Not yet recruiting	Drug: Alpelisib + Paclitaxel	Solid Tumor\|Stomach Cancer	Seoul National University Bundang Hospital	September 1 2020	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?
Answer:
S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.
Question 2:
the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?
Answer:
Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Choose Your Country or Region

By Signaling Pathways

By product type

Paclitaxel